336 related articles for article (PubMed ID: 11712820)
1. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
[TBL] [Abstract][Full Text] [Related]
2. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
3. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
Bottoni U; Bonaccorsi P; Devirgiliis V; Panasiti V; Borroni RG; Trasimeni G; Clerico R; Calvieri S
Jpn J Clin Oncol; 2005 Sep; 35(9):507-13. PubMed ID: 16120623
[TBL] [Abstract][Full Text] [Related]
4. High-dose platinum combination therapy in pretreated patients with disseminated melanoma.
Hofmann MA; Gabriel V; Milling A; Kiecker F; Sterry W; Trefzer U
Chemotherapy; 2007; 53(6):422-8. PubMed ID: 17952002
[TBL] [Abstract][Full Text] [Related]
5. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma.
Agarwala SS; Ferri W; Gooding W; Kirkwood JM
Cancer; 1999 May; 85(9):1979-84. PubMed ID: 10223239
[TBL] [Abstract][Full Text] [Related]
6. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy of disseminated malignant melanoma with imidazol carboxamide (DTIC) and cyclophosphamide. Preliminary results.
Rudolf Z; Plesnicar S
Anticancer Res; 1982; 2(1-2):37-9. PubMed ID: 7051959
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
Cancer; 1989 May; 63(9):1676-80. PubMed ID: 2467736
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
[TBL] [Abstract][Full Text] [Related]
11. Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.
Jelić S; Babović N; Stamatović L; Kreacić M; Matković S; Popov I
Med Oncol; 2001; 18(3):189-95. PubMed ID: 11917943
[TBL] [Abstract][Full Text] [Related]
12. Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
Samson MK; Baker LH; Izbicki RM; Ratanatharathorn V
Cancer Treat Rep; 1976 Sep; 60(9):1369-71. PubMed ID: 65223
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of the efficacy of modern first, second, and third line regimes of chemotherapy in patients with disseminated cutaneous melanoma].
Akimov MA; Gershanovich ML
Vopr Onkol; 2001; 47(4):428-35. PubMed ID: 11710284
[TBL] [Abstract][Full Text] [Related]
14. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
Hofmann MA; Sterry W; Trefzer U
Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
McClay EF; Mastrangelo MJ; Bellet RE; Berd D
Cancer Treat Rep; 1987 May; 71(5):465-9. PubMed ID: 3567970
[TBL] [Abstract][Full Text] [Related]
16. Unexpected clinical outcome in a patient with liver and brain metastasis from melanoma.
Nuzzo C; Zeuli M; Ferraresi V; Ciccarese M; Pelligrini D; Cognetti F
Anticancer Res; 2008; 28(2B):1429-31. PubMed ID: 18505091
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
18. [Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
Li EX; Zhang YT; Shang JT; Xu Z; Geng Y; Li SM; Shi F; Wu YY
Ai Zheng; 2006 Aug; 25(8):1048-51. PubMed ID: 16965692
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL
Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287
[TBL] [Abstract][Full Text] [Related]
20. [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
Gershanovich ML; Akimov MA
Vopr Onkol; 2004; 50(2):179-83. PubMed ID: 15176220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
